Sensus Healthcare, Inc. (SRTS) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sensus Healthcare Third Quarter Financial Results Feature Revenue Growth of 32%
November 1, 2018 4:02 PM EDTBOCA RATON, Fla., Nov. 1, 2018 /PRNewswire/ --Â Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces financial results for the three and nine months ended September 30, 2018.
Highlights from the third quarter of 2018 and recent weeks include:
Continued double-digit growth with revenues of $6.3 million, up 32% over the prior-year period Narrowed net loss to $(0.5) million, or $(0.03) per share, from $(1.0) million, or $(0.07) per share a year ago Adjusted EBITDA, a non-GAAP financial measure, improved to $(0.1)... More